The current options for monitoring the course of solid tumors are essentially limited to imaging methods and conventional markers. The sensitivity and specificity of computer tomography and the measurement of carcinoembryonic antigen in the blood are limited in colorectal cancer (colon cancer). Thus, a therapeutic consequence can often only be drawn in the case of a disease or progression that can be clinically or morphologically ascertained.
The development and preproduction of an inexpensive and easy-to-use functional sample of a detection platform based on digital PCR (dPCR) with integrated sample preparation for early therapy optimization and treatment of colorectal cancer.
Digital camera-based detection system and software of a processing device for the automation of routine clinical diagnosis of circulating tumor DNA
Other partners from industry and research:
Bioron GmbH, Ludwigshafen
velixX GmbH, Mannheim
TDC GmbH, Mannheim
Hahn-Schickard-Gesellschaft für angewandte Forschung e.V., Freiburg